Recipharm AB (RECI B):企業の財務・戦略的SWOT分析

◆英語タイトル:Recipharm AB (RECI B) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C15508
◆発行会社(調査会社):GlobalData
◆発行日:2019年3月
◆ページ数:53
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Recipharm AB (RECI B) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Recipharm AB (Recipharm) is a contract development and manufacturing organization (CDMO) that offers manufacturing, and development and technology services. The company’s manufacturing segment provides contract manufacturing of pharmaceuticals such as semi-solids, and oral liquids, solid dose, sterile products, besides clinical trial materials including APIs and other drugs. Recipharm’s development and technology segment offers raw material supply, formulation development and development of validated analytical methods, among others. The company operates in the UK, Germany, Spain, Italy, Sweden, France, and others. Recipharm is headquartered in Stockholm, Sweden.

Recipharm AB Key Recent Developments

Feb 28,2019 Recipharm achieves new ISO 45001 certification to support sustainability efforts
Feb 21,2019 Recipharm publishes its report for the fourth quarter and full year 2018
Feb 14,2019 Recipharm announces all its facilities are ready for EU serialisation
Feb 12,2019 Recipharm names new Director of Business Management

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Recipharm AB – Key Facts
Recipharm AB – Key Employees
Recipharm AB – Key Employee Biographies
Recipharm AB – Major Products and Services
Recipharm AB – History
Recipharm AB – Company Statement
Recipharm AB – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Recipharm AB – Business Description
Business Segment: D&T
Overview
Performance
Business Segment: MFG-SL
Overview
Performance
Business Segment: MFG-SO
Overview
Performance
Geographical Segment: France
Performance
Geographical Segment: Germany
Performance
Geographical Segment: India
Performance
Geographical Segment: Italy
Performance
Geographical Segment: Other
Performance
Geographical Segment: Portugal
Performance
Geographical Segment: Spain
Performance
Geographical Segment: Sweden
Performance
Recipharm AB – Corporate Strategy
Recipharm AB – SWOT Analysis
SWOT Analysis – Overview
Recipharm AB – Strengths
Recipharm AB – Weaknesses
Recipharm AB – Opportunities
Recipharm AB – Threats
Recipharm AB – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Recipharm AB, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 28, 2019: Recipharm achieves new ISO 45001 certification to support sustainability efforts
Feb 21, 2019: Recipharm publishes its report for the fourth quarter and full year 2018
Feb 14, 2019: Recipharm announces all its facilities are ready for EU serialisation
Feb 12, 2019: Recipharm names new Director of Business Management
Dec 19, 2018: Recipharm to potentially end operations in Ashton-under-Lyne facility
Nov 08, 2018: Recipharm publishes its interim report January – September 2018
Oct 25, 2018: Manufacturing licence restriction at Recipharm, Ashton-u-Lyne, UK facility
Oct 19, 2018: Recipharm continues manufacturing operations in Hoganas, Sweden
Oct 09, 2018: Recipharm releases first serialised products to Europe
Oct 03, 2018: Recipharm names Tobias Hagglov as Chief Financial Officer
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Recipharm AB, Key Facts
Recipharm AB, Key Employees
Recipharm AB, Key Employee Biographies
Recipharm AB, Major Products and Services
Recipharm AB, History
Recipharm AB, Other Locations
Recipharm AB, Subsidiaries
Recipharm AB, Key Competitors
Recipharm AB, Ratios based on current share price
Recipharm AB, Annual Ratios
Recipharm AB, Annual Ratios (Cont...1)
Recipharm AB, Annual Ratios (Cont...2)
Recipharm AB, Interim Ratios
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Recipharm AB, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Recipharm AB, Performance Chart (2014 - 2018)
Recipharm AB, Ratio Charts
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Recipharm AB, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

★海外企業調査レポート[Recipharm AB (RECI B):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sanford Burnham Prebys Medical Discovery Institute:製薬・医療:M&Aディール及び事業提携情報
    Summary Sanford Burnham Prebys Medical Discovery Institute (SBP) is a non-profit public benefit institute that offers medical research services. The institute offers research programs in the field of tumor initiation and maintenance, cancer metabolism and signaling networks, tumor microenvironment a …
  • Arrow Energy Pty Ltd:企業の戦略的SWOT分析
    Arrow Energy Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Drugs for Neglected Diseases initiative-製薬・医療分野:企業M&A・提携分析
    Summary Drugs for Neglected Diseases initiative (DNDi) is a research center that discovers and develops new drugs. The center develops therapeutics for the treatment of various diseases. It offers treatments which include ASAQ, ASMQ, NECT, SSG&PM and pediatric benznidazole. DNDi also offers products …
  • National Insurance Corporation of Eritrea Share Company:企業の戦略的SWOT分析
    National Insurance Corporation of Eritrea Share Company - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key c …
  • Global Insurance Management Limited
    Global Insurance Management Limited - Strategy, SWOT and Corporate Finance Report Summary Global Insurance Management Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Asahi Kasei Corp (3407):企業の財務・戦略的SWOT分析
    Asahi Kasei Corp (3407) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • IBEX Technologies Inc (IBT):企業の財務・戦略的SWOT分析
    Summary IBEX Technologies Inc (IBEX) is a manufacturer and marketer of high-purity proprietary enzymes and recombinant from flavobacterium heparinum. The company provides enzymes such as heparinase I, heparinase II, heparinase III, chondroitinase AC and chondroitinase B. Its assays allow for the stu …
  • Aarti Drugs Ltd (AARTIDRUGS):企業の財務・戦略的SWOT分析
    Summary Aarti Drugs Ltd (ADL), a subsidiary of Aarti Group of Industries is a contract manufacturer of pharmaceutical products that offers therapeutic products, ingredients, bulk drugs, and chemicals. The company's products include active pharmaceutical ingredients, pharma intermediates, and special …
  • Bancolombia SA (BCOLOMBIA):企業の財務・戦略的SWOT分析
    Bancolombia SA (BCOLOMBIA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • PHC Corp:医療機器:M&Aディール及び事業提携情報
    Summary PHC Corp (PHC), formerly Panasonic Healthcare Co Ltd, a subsidiary of PHC Holdings Corp, is a medical device company that provides vitro diagnostics, medical IT and life science equipment. The company provides biomedical systems such as preservation systems, incubation systems, sterilization …
  • Tel Aviv Sourasky Medical Center:製薬・医療:M&Aディール及び事業提携情報
    Summary Tel Aviv Sourasky Medical Center (Sourasky Medical) is an academic medical center that provides patient-centered care, research and education services. The center offers services in the areas of cardiology, dermatology, gastroenterology, general surgery, genetics, emergency medicine, rheumat …
  • Highland Gold Mining Limited
    Highland Gold Mining Limited - Strategy, SWOT and Corporate Finance Report Summary Highland Gold Mining Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Sensus Healthcare Inc (SRTS):医療機器:M&Aディール及び事業提携情報
    Summary Sensus Healthcare Inc (Sensus) designs, manufactures and markets proprietary medical devices for the treatment of various types of cancers and skin diseases. The company offers superficial radiation therapy (SRT) technology based non-surgical treatment options for patients suffering from var …
  • Cti Engineering Co Ltd
    Cti Engineering Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Cti Engineering Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Straumann Holding AG (STMN):企業の財務・戦略的SWOT分析
    Straumann Holding AG (STMN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Robert Half International Inc. (RHI):企業の財務・戦略的SWOT分析
    Robert Half International Inc. (RHI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Sumitomo Electric Industries Ltd (5802):企業の財務・戦略的SWOT分析
    Sumitomo Electric Industries Ltd (5802) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • JSC Insurance Company Aldagi:企業の戦略・SWOT・財務情報
    JSC Insurance Company Aldagi - Strategy, SWOT and Corporate Finance Report Summary JSC Insurance Company Aldagi - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Genel Energy Plc (GENL):石油・ガス:M&Aディール及び事業提携情報
    Summary Genel Energy Plc (Genel) is an independent upstream oil and gas company. It carries out acquisition, exploration, and production operations. It has interest in Taq Taq and Tawke in the Kurdistan region. The company develops the Miran and Bina Bawi gas fields in Zagros Fold belt in the Kurdis …
  • Western Iowa Energy LLC:企業の戦略的SWOT分析
    Western Iowa Energy LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆